-
CStone's PD-L1 antibody treatment of R/R ENKTL's clinical application was approved by the U.S. FDA
Time of Update: 2020-09-28
Keystone Pharmaceuticals, a biopharmaceutical company focused on the development of innovative oncology immunotherapy and precision therapy drugs, announced that its experimental new drug (IND) application for PD-L1 antibody Shuglidan (CS1001) single-drug treatment for recurrence or refractic endocyst natural killer cells/T-cell lymphoma (R/R ENKTL) has been reviewed by the FDA.
-
Nature: New research provides new insights into the development of better flu vaccines.
Time of Update: 2020-09-28
of the three volunteers, both memory B cells in the lymph nodes and initial B cells responded to the vaccine strain, suggesting that the vaccine had initiated a process of inducing lasting immunity to the new strain of influenza virus.
-
Mosquitoes spread so many diseases, how can they be all right? Science reveals the specialities of mosquito immune cells.
Time of Update: 2020-09-28
we also looked at mosquitoes infected with malaria parasites, studied the immune response of mosquitoes at the molecular level for the first time, and identified cell types and signaling path paths involved in this process.
-
Progress has been made in the study of natural immunomodulation mechanisms by acetylation modification.
Time of Update: 2020-09-28
HDAC3 can directly deacetylize TBK1 Lys241, Lys692 bits to enhance TBK1 kinase activity, wherein TBK1 Lys241 bits of acetylation modification levels in the early stimulation of the virus significantly enhanced, followed by natural immune signaling pathacts to reduce.
-
The world's only intestinal selective anti-inflammatory drug! Takeda Enteryvio (Anjiyou) subskin preparation u.S. project update, intravenous preparations listed in China!
Time of Update: 2020-09-27
As mentioned earlier, on December 20, 2019, the company received a full response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding a biological product licensing application (BLA) filed by the company for the maintenance of entervio SC preparations for adult patients with moderate to severe ulcerative colitis (UC).
-
J Thorac Oncol: Study reveals key immune cells that kill lung cancer cells.
Time of Update: 2020-09-27
study of preclinical and patient samples of small cell lung cancer (SCLC), NK cells, rather than T cells, were found to be critical to slowing the aggressive spread of cancer.
"Our study shows that immunotherapy that harnesses the anti-tumor power of NK cells may be more effective for SCLC.
-
Nature: Revealing the 'culprits' that contribute to the body's cancer as we age
Time of Update: 2020-09-27
September 4, 2020 // -- As the body converts food into energy, our bodies accumulate a lot of "junk" as we age, according to a recent study published in the international journal Nature, from the Weil
-
Non-cystic fibrosis bronchroid dilation (NCFBE) breakthrough drug! The pioneering DEP1 inhibitor brensocatib significantly reduces the risk of lung increase!
Time of Update: 2020-09-27
results showed that the study reached its main endpoint: 2 doses (10mg and 25mg) of brensocatib significantly extended the time of first lung exacerbation during treatment for 24 weeks (6 months) compared to placebo (10mg group p=0.03; 25mg group p=0.04).
-
Cell Res: Breakthrough! Chinese scientists have discovered for the first time that SARS-CoV-2 could potentially infect human nerve cells and brain-like organs!
Time of Update: 2020-09-27
September 4, 2020 // -- In a recent study published in the international journal Cell Research, scientists from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences and the University of Hong Kong found that SARS-CoV-2 may infect human nerve cells and brain-like organs.
-
Nat Commun: The study reveals subtypes and differentiation pathways in natural T cells.
Time of Update: 2020-09-27
a recent study, researchers from South Korea discovered the development of immune cells, a process that allows these memory cells to form early without encountering pathogens.
-
New anti-inflammatory drugs! Bronger Ingeham terminates clinical development of AOC3 inhibitor BI1467335: there is a risk of drug interaction!
Time of Update: 2020-09-27
September 08, 2020 // -- Boehringer Ingelheim and Pharmaxis recently jointly announced the termination of the development of BI1467335 for the treatment of moderate to non-proliferative diabetic retinal lesions (NPDR).
-
Adv Sci: Explains the molecular mechanisms by which tumor cells divide cells in crowded environments.
Time of Update: 2020-09-27
5, 2020 // -- In a recent study published in the international journal Advanced Science, scientists from the Dresden University of Technology and others have revealed molecular mechanisms by which cancer cells divide in crowded tumor tissue, and researchers have linked this mechanism to signs of cancer progression and metastasis (the intersessional transformation process, the EMT process).
-
Physiol Geno: Uncovering the mysterious link between poor sleep quality, high blood pressure and the body's gut microbiome!
Time of Update: 2020-09-27
Maki et al, Sleep fragmentation increases blood pressure and is associated with alterations in the gut microbiome and fecal metabolome in rats, Physi Genomics (2020).
-
Cell: Clinical studies have confirmed that vaccination of card seedlings can reduce respiratory infections by 75% in older adults.
Time of Update: 2020-09-27
at Radburg University Medical Center, Mihai Netea, a professor of experimental medicine, is studying the protective effects of card-based seedlings on a variety of infections, known as "trained immunity." Two years ago, we started the ACTATE study to see if vaccinations protect vulnerable older people from infection, " says Professor Netea.
-
New Crown Outbreak: 27.29 million! Sanofi/Regenerative IL-6 inhibitor Kevzara treats (critical) critically ill patients with Phase III clinical failure!
Time of Update: 2020-09-27
recently, Sanofi released the latest results from a global Phase III clinical trial outside the United States to evaluate the treatment of severe and critically ill COVID-19 hospitalized patients with the anti-inflammatory drug Kevzara.
-
New coronary antibodies can last up to four months in the body, according to new research in Iceland.
Time of Update: 2020-09-27
more than 90 percent of new crown patients in Iceland have increased antibody levels after diagnosis and then remained stable for up to four months, a new study showed, Reuters reported on Sept.
-
Nature: How can scientists analyze lymph nodes to help cancer cells spread?
Time of Update: 2020-09-27
4, 2020 // -- Clinicians have known for decades that multiple types of cancer cells spread to the lymph nodes before spreading through the blood to distant organs, and scientists from institutions suc
-
Nature: Scientists reveal why cancer cells evade the immune system of host bodies.
Time of Update: 2020-09-27
Photo Source: University of Cambridge researcher Weiping Zou says it's not known if these problems can be linked, and in this study we were able to piece together these puzzles to illustrate how they work; in the paper, researchers found a link between three separate puzzles, suggesting that targeting methionine transport proteins in tumor cells may help immunotherapy fight more effectively against more cancers.
-
Innovative triple therapy for asthma! Novart Enerzair Breezhaler: High doses significantly reduce asthma exacerbation compared to medium doses!
Time of Update: 2020-09-27
" In early July, Enerzair Breezhaler was approved by the European Union as a maintenance therapy for adults with asthma who received a combination of long-acting beta2-receiving astrations (LABA) and high-dose inhaled corticosteroids (ICS) to maintain a condition that did not adequately control the condition and experienced one or more acute asthma exacerbations in the past year.
-
Nature: Uncover the characteristics of the special HIV library in the body of the HIV elite controller!
Time of Update: 2020-09-27
September 4, 2020 // -- In a recent study published in the international journal Nature, scientists from Massachusetts General Hospital and other institutions successfully sequenced hundreds of millio
